(2S,3S,4S,5S)-2,5-bis<<(tert-butyloxy)carbonyl>amino>-3,4-dihydroxy-1,6-diphenylhexane | 129491-64-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (2S,3S,4S,5S)-2,5-bis<<(tert-butyloxy)carbonyl>amino>-3,4-dihydroxy-1,6-diphenylhexane
• 英文别名: (2S,3S,4S,5S)-2,5-bis[(1,1-dimethylethoxy)carbonyl]amino-1,6-diphenyl-3,4-dihydroxyhexane；(2S,3S,4S,5S)-2,5-Bis{[(tert-butyloxy)carbonyl]amino}-3,4-dihydroxy-1,6-diphenylhexane；(2S,3S,4S,5S)-2,5-bis[(tert-butoxycarbonyl)amino]-1,6-diphenylhexane-3,4-diol；N,N'-bis-(tert.-butoxycarbonyl)-2S,5S-diamino-1,6-diphenylhexane-3S,4S-diol；(2S,3S,4S,5S)-2,5-bis[[(tert-butyloxy)carbonyl]amino]-3,4-dihydroxy-1,6-diphenylhexane；((1S,2S,3S,4S)-1-Benzyl-4-tert-butoxycarbonylamino-2,3-dihydroxy-5-phenyl-pentyl)-carbamic acid tert-butyl ester；tert-butyl N-[(2S,3S,4S,5S)-3,4-dihydroxy-5-[(2-methylpropan-2-yl)oxycarbonylamino]-1,6-diphenylhexan-2-yl]carbamate
• CAS: 129491-64-1
• 化学式: C₂₈H₄₀N₂O₆
• 分子量: 500.635
• InChiKey: XEFORNHNQOHGSE-ZJZGAYNASA-N

物化性质

• 熔点：
  181-185 °C
• 沸点：
  680.3±55.0 °C(Predicted)
• 密度：
  1.150±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  36
• 可旋转键数：
  13
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  117
• 氢给体数：
  4
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  (2S,3S,4S,5S)-2,5-bis<<(tert-butyloxy)carbonyl>amino>-3,4-dihydroxy-1,6-diphenylhexane 在 二氧化铂 作用下， 以 溶剂黄146 为溶剂， 生成 (2S,3S,4S,5S)-2,5-bis[(tert-butoxycarbonyl)amino]-1,6-dicyclohexylhexane-3,4-diol
  参考文献：
  名称：

  Inhibitors of retroviral proteases

  摘要：

  本发明涉及公式I的化合物，其中A，Y，R.sup.2，R.sup.3，R.sup.4，R.sup.5，R.sup.6，l，m和标有*的相应基团如说明书中所述，以及它们的制备方法和它们用于抑制逆转录病毒蛋白酶的用途。

  公开号：

  US05712417A1
• 作为产物：
  描述：

  N-benzyl-N-(tert-butoxycarbonyl)-L-phenylalaninal 在 四氧化锇 吡啶 、 disodium hydrogenphosphate 、 正丁基锂 、 sodium amalgam 、 sodium 、 N-甲基吗啉氧化物 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 氨 、 水 、 叔丁醇 为溶剂， 反应 37.5h， 生成 (2S,3S,4S,5S)-2,5-bis<<(tert-butyloxy)carbonyl>amino>-3,4-dihydroxy-1,6-diphenylhexane
  参考文献：
  名称：

  Synthesis of novel C2-symmetric and pseudo C2-symmetric based diols, epoxides and dideoxy derivatives of HIV protease inhibitors

  摘要：

  The Julia's olefination reaction between the sulfone derivative (10) and the aldehyde (13) (both obtained from L-phenylalanine) followed by debenzylation led to the formation (2S,5S,3E)-2,5-bis-[( I,l-dimethyl ethoxy)-carbonyl]amino-l ,6-diphenylhex-3-ene (4a). Similarly (2S,5S,3E)-2,5-bis- [(1,1-dimethylethoxy)-carbonyl]amino- 1-phenyl-6-(p-methoxy)phenylhex-3-ene (4b) was also synthesised from the sulfone (10) and L-tyrosine derived aldehyde (21). These novel intermediates (4a and 4b) were subjected to epoxidation, hydrogenation, hydroboration-oxidation and dihydroxylation reactions. These modifications resulted in the synthesis of known and unknown, C-2-symmetric and pseudo-C-2-symmetric diamino-epoxides, dideoxy derivatives, diols and deoxy diols based HIV protease inhibitors. (C) 1997 Published by Elsevier Science Ltd.

  DOI：

  10.1016/s0040-4020(97)00160-9

文献信息

• A short approach to the synthesis of the ritonavir and lopinavir core and its C-3 epimer via cross metathesis
  作者：Errabelli Ramu、B. Venkateswara Rao

  DOI：10.1016/j.tetasy.2009.09.003

  日期：2009.10

  A short synthesis of hydroxyethylene dipeptide isostere, a core unit of the HIV-protease inhibitors ritonavir and lopinavir, its C-3 epimer and C2 symmetric diamino diol is described. The crucial aspects of the synthesis are self-cross metathesis and exploitation of C2-symmetric of the metathesis product 8 to obtain the required skeleton.

  描述了一种简短合成的羟乙基二肽等排物，它是HIV蛋白酶抑制剂利托那韦和洛匹那韦的核心单元，其C-3差向异构体和C 2对称二氨基二醇。合成的关键方面是自交叉复分解和利用复分解产物8的C 2对称来获得所需的骨架。
• Retroviral protease inhibiting compounds
  申请人：Abbott Laboratories

  公开号：US05545750A1

  公开（公告）日：1996-08-13

  A retroviral protease inhibiting compound of the formula A--X--B or a pharmaceutically acceptable salt, prodrug or ester thereof, wherein X is a linking group; A is (1) substituted amino, (2) substituted carbonyl, (3) functionalized imino, (4) functionalized alkyl, (5) functionalized acyl, (6) functionalized heterocyclic or (7) functionalized (heterocyclic)alkyl; and B is (1) substituted carbonyl independently defined as herein, (2) substituted amino independently defined as herein, (3) functionalized imino independently defined as herein, (4) functionalized alkyl independently defined as herein, (5) functionalized acyl independently defined as herein, (6) functionalized heterocyclic independently defined as herein or (7) functionalized (heterocyclic)alkyl independently defined as herein.

  一种具有以下结构的逆转录病毒蛋白酶抑制剂化合物A-X-B或其药学上可接受的盐、前药或酯，其中X是连接基；A是（1）取代的氨基，（2）取代的羰基，（3）官能化的亚胺基，（4）官能化的烷基，（5）官能化的酰基，（6）官能化的杂环基或（7）官能化的（杂环）烷基；B是（1）独立于此处定义的取代的羰基，（2）独立于此处定义的取代的氨基，（3）独立于此处定义的官能化亚胺基，（4）独立于此处定义的官能化烷基，（5）独立于此处定义的官能化酰基，（6）独立于此处定义的官能化杂环基或（7）独立于此处定义的官能化（杂环）烷基。
• Inhibitoren retroviraler Proteasen
  申请人：HOECHST AKTIENGESELLSCHAFT

  公开号：EP0428849A2

  公开（公告）日：1991-05-29

  Die vorliegende Erfindung betrifft Verbindung der Formel I worin A, Y, R², R³, R⁴, R⁵, R⁶, l, m, sowie die entsprechenden mit * versehenen Reste wie in der Beschreibung angegeben definiert sind, ein Verfahren zu deren Herstellung, sowie ihre Verwendung zur Hemmung retroviraler Proteasen.

  本发明涉及一种式 I 的化合物 其中 A、Y、R²、R³、R⁴、R⁵、R⁶、l、m 和标有 * 的相应基团的定义、制备方法及其用于抑制逆转录病毒蛋白酶的用途。
• Intermediates for preparating non-peptide retroviral protease inhibitors
  申请人：ABBOTT LABORATORIES

  公开号：EP0839798A2

  公开（公告）日：1998-05-06

  Intermediates, for preparing non-peptide retroviral protease inhibitors, said intermediates having the formula: or an acid addition salt thereof or an N-protected derivative thereof wherein at each occurrence the N-protecting group is independently selected from the group consisting of formyl, acetyl, pivaloyl, t-butylacetyl, t-butyloxycarbonyl, benzyloxycarbonyl, benzyl and isopropylaminocarbonyl; or said intermediates being selected from: (2S,3R,4S,5S)-2,5-di-(N-(Cbz-valinyl)amino)-3,4-dihydroxy-1,6-diphenylhexane; (2S,3S,4S,5S)-2,5-di-(N-(Cbz-valinyl)amino)-3,4-dihydroxy-1,6-diphenylhexane; (2S,3R,4R,5S)-2,5-di-(N-(Cbz-valinyl)amino)-3,4-dihydroxy-1,6-diphenylhexane; (2S,3S,4S,5S)-2,5-di-(N-(valinyl)amino)-3,4-dihydroxy-1,6-diphenylhexane; (2S,3R,4S,5S)-2,5-di-(N-(valinyl)amino)-3,4-dihydroxy-1,6-diphenylhexane; (2S,3R,4R,5S)-2,5-di-(N-(valinyl)amino)-3,4-dihydroxy-1,6-diphenylhexane; (2S,3S,4R,5S)-2-(N-(t-butyloxy)carbonyl)amino)-5-(N-(Cbz-valinyl)amino)-3,4-dihydroxy-1,6-diphenylhexane; 2-(N-benzyl-N-(benzyloxycarbonyl)amino)-5-(t-butyloxycarbonylamino)-1,6-diphenyl-3-hexene-3,4-oxide; 2-amino-5-(t-butyloxycarbonylamino)-1,6-diphenyl-3-hexene-3,4-oxide; and 2,5-di-(t-butyloxycarbonylamino)-1,6-diphenyl-3-hexene-3,4-oxide; or an acid addition salt thereof.

  用于制备非肽类逆转录病毒蛋白酶抑制剂的中间体，所述中间体具有以下式子： 或其酸加成盐或其 N-保护衍生物，其中每次出现时，N-保护基独立选自甲酰、乙酰、特戊酰、叔丁基乙酰、叔丁氧羰基、苄氧羰基、苄基和异丙氨基羰基组成的组；或所述中间体选自以下物质 (2S,3R,4S,5S)-2,5-二(N-(Cbz-缬氨酰)氨基)-3,4-二羟基-1,6-二苯基己烷； (2S,3S,4S,5S)-2,5-二(N-苄氧羰基缬氨酰氨基)-3,4-二羟基-1,6-二苯基己烷； (2S,3R,4R,5S)-2,5-二(N-苄氧羰基缬氨酰氨基)-3,4-二羟基-1,6-二苯基己烷； (2S,3S,4S,5S)-2,5-二(N-(缬氨酰)氨基)-3,4-二羟基-1,6-二苯基己烷； (2S,3R,4S,5S)-2,5-二(N-(缬氨酰)氨基)-3,4-二羟基-1,6-二苯基己烷； (2S,3R,4R,5S)-2,5-二(N-(缬氨酰)氨基)-3,4-二羟基-1,6-二苯基己烷； (2S,3S,4R,5S)-2-(N-(叔丁氧基)羰基)氨基)-5-(N-(Cbz-缬氨酰)氨基)-3,4-二羟基-1,6-二苯基己烷； 2-(N-苄基-N-(苄氧羰基)氨基)-5-(叔丁氧羰基氨基)-1,6-二苯基-3-己烯-3,4-氧化物； 2-氨基-5-(叔丁氧羰基氨基)-1,6-二苯基-3-己烯-3,4-氧化物；以及 2,5-二（叔丁氧羰基氨基）-1,6-二苯基-3-己烯-3,4-氧化物； 或其酸加成盐。
• Facile and Highly Stereoselective Synthesis of the C2-Symmetrical Diamino Diol Core-Unit of HIV-1 Protease Inhibitors and of Their Symmetrical and Unsymmetrical Analogs from Lithiated 2-(Dibenzylamino)alkyl Carbamates: Oxidative Dimerization
  作者：B. Weber

  DOI：10.1055/s-1999-3576

  日期：1999.9